JP2012519692A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012519692A5 JP2012519692A5 JP2011553061A JP2011553061A JP2012519692A5 JP 2012519692 A5 JP2012519692 A5 JP 2012519692A5 JP 2011553061 A JP2011553061 A JP 2011553061A JP 2011553061 A JP2011553061 A JP 2011553061A JP 2012519692 A5 JP2012519692 A5 JP 2012519692A5
- Authority
- JP
- Japan
- Prior art keywords
- suspension
- composition
- peg
- item
- active agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000725 suspension Substances 0.000 claims description 85
- 239000000203 mixture Substances 0.000 claims description 44
- 239000013543 active substance Substances 0.000 claims description 26
- 229920001223 polyethylene glycol Polymers 0.000 claims description 20
- 229920002538 Polyethylene Glycol 20000 Polymers 0.000 claims description 14
- 102000027426 receptor tyrosine kinases Human genes 0.000 claims description 14
- 108091008598 receptor tyrosine kinases Proteins 0.000 claims description 14
- 239000003112 inhibitor Substances 0.000 claims description 12
- 239000002245 particle Substances 0.000 claims description 10
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims description 10
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 10
- 229920000053 polysorbate 80 Polymers 0.000 claims description 10
- 229940068968 polysorbate 80 Drugs 0.000 claims description 10
- 206010029113 Neovascularisation Diseases 0.000 claims description 9
- 208000022873 Ocular disease Diseases 0.000 claims description 9
- 229920002560 Polyethylene Glycol 3000 Polymers 0.000 claims description 8
- 239000004037 angiogenesis inhibitor Substances 0.000 claims description 8
- MPVGZUGXCQEXTM-UHFFFAOYSA-N linifanib Chemical group CC1=CC=C(F)C(NC(=O)NC=2C=CC(=CC=2)C=2C=3C(N)=NNC=3C=CC=2)=C1 MPVGZUGXCQEXTM-UHFFFAOYSA-N 0.000 claims description 8
- 238000002347 injection Methods 0.000 claims description 7
- 239000007924 injection Substances 0.000 claims description 7
- 239000002202 Polyethylene glycol Substances 0.000 claims description 6
- 229920001664 tyloxapol Polymers 0.000 claims description 6
- MDYZKJNTKZIUSK-UHFFFAOYSA-N tyloxapol Chemical compound O=C.C1CO1.CC(C)(C)CC(C)(C)C1=CC=C(O)C=C1 MDYZKJNTKZIUSK-UHFFFAOYSA-N 0.000 claims description 6
- 229960004224 tyloxapol Drugs 0.000 claims description 6
- 229940100654 ophthalmic suspension Drugs 0.000 claims description 5
- 239000008118 PEG 6000 Substances 0.000 claims description 4
- 229920002584 Polyethylene Glycol 6000 Polymers 0.000 claims description 4
- 229920001213 Polysorbate 20 Polymers 0.000 claims description 4
- 206010064930 age-related macular degeneration Diseases 0.000 claims description 4
- 239000002736 nonionic surfactant Substances 0.000 claims description 4
- 239000008389 polyethoxylated castor oil Substances 0.000 claims description 4
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims description 4
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims description 4
- 229940068977 polysorbate 20 Drugs 0.000 claims description 4
- 229940124617 receptor tyrosine kinase inhibitor Drugs 0.000 claims description 4
- 230000008728 vascular permeability Effects 0.000 claims description 4
- 206010012689 Diabetic retinopathy Diseases 0.000 claims description 2
- 208000008069 Geographic Atrophy Diseases 0.000 claims description 2
- 208000001344 Macular Edema Diseases 0.000 claims description 2
- 206010025415 Macular oedema Diseases 0.000 claims description 2
- 206010046851 Uveitis Diseases 0.000 claims description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 claims description 2
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 2
- 230000002137 anti-vascular effect Effects 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 claims description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 2
- 238000009472 formulation Methods 0.000 claims description 2
- 230000003902 lesion Effects 0.000 claims description 2
- 208000002780 macular degeneration Diseases 0.000 claims description 2
- 201000010230 macular retinal edema Diseases 0.000 claims description 2
- 208000035475 disorder Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 description 12
- 230000033115 angiogenesis Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000002207 retinal effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15698409P | 2009-03-03 | 2009-03-03 | |
| US61/156,984 | 2009-03-03 | ||
| PCT/US2010/025998 WO2010101971A1 (en) | 2009-03-03 | 2010-03-03 | Pharmaceutical composition for delivery of receptor tyrosine kinase inhibiting (rtki) compounds to the eye |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012519692A JP2012519692A (ja) | 2012-08-30 |
| JP2012519692A5 true JP2012519692A5 (https=) | 2013-03-07 |
| JP5583145B2 JP5583145B2 (ja) | 2014-09-03 |
Family
ID=42678477
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011553061A Expired - Fee Related JP5583145B2 (ja) | 2009-03-03 | 2010-03-03 | レセプターチロシンキナーゼ阻害（ＲＴＫｉ）化合物の眼への送達のための薬学的組成物 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20100226992A1 (https=) |
| EP (1) | EP2403342A4 (https=) |
| JP (1) | JP5583145B2 (https=) |
| KR (1) | KR20110123789A (https=) |
| CN (2) | CN105362221A (https=) |
| AU (1) | AU2010221438C1 (https=) |
| BR (1) | BRPI1008920A2 (https=) |
| CA (1) | CA2753837A1 (https=) |
| MX (1) | MX2011008680A (https=) |
| WO (1) | WO2010101971A1 (https=) |
| ZA (1) | ZA201105506B (https=) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2494108C2 (ru) | 2006-04-07 | 2013-09-27 | Аерпио Терапетикс, Инк. | Антитела, которые связывают человеческий белок бета-тирозин фосфатазу (нртрвета), и их использование |
| US7622593B2 (en) | 2006-06-27 | 2009-11-24 | The Procter & Gamble Company | Human protein tyrosine phosphatase inhibitors and methods of use |
| TW201023912A (en) | 2008-12-05 | 2010-07-01 | Alcon Res Ltd | Pharmaceutical suspension |
| US8912236B2 (en) | 2009-03-03 | 2014-12-16 | Alcon Research, Ltd. | Pharmaceutical composition for delivery of receptor tyrosine kinase inhibiting (RTKi) compounds to the eye |
| ES2726946T3 (es) | 2009-07-06 | 2019-10-10 | Aerpio Therapeutics Inc | Derivados de benzosulfonamida, composiciones de los mismos y su uso en la prevención de la metástasis de las células cancerosas |
| WO2013056240A1 (en) | 2011-10-13 | 2013-04-18 | Aerpio Therapeutics, Inc. | Methods for treating vascular leak syndrome and cancer |
| PE20142103A1 (es) * | 2011-12-14 | 2015-01-11 | Abbvie Inc | Composiciones que contienen inhibidores de quinasas |
| EP2825166A1 (en) * | 2012-03-12 | 2015-01-21 | Allergan, Inc. | Method of treating ophthalmic conditions with kinase inhibitors |
| US20150050277A1 (en) | 2013-03-15 | 2015-02-19 | Aerpio Therapeutics Inc. | Compositions and methods for treating ocular diseases |
| KR20160060656A (ko) | 2013-09-20 | 2016-05-30 | 산텐 세이야꾸 가부시키가이샤 | 폴리에틸렌글리콜 함유 조성물 |
| EP3116503A4 (en) | 2014-03-14 | 2017-08-23 | Aerpio Therapeutics, Inc. | Hptp-beta inhibitors |
| RU2768652C1 (ru) * | 2014-09-17 | 2022-03-24 | Паноптика, Инк. | Офтальмологические составы для доставки лекарств и защиты переднего отдела глаза |
| WO2016197005A1 (en) * | 2015-06-05 | 2016-12-08 | Kato Pharmaceuticals, Inc. | Extended release urea compositions |
| TWI700085B (zh) * | 2015-06-22 | 2020-08-01 | 新源生物科技股份有限公司 | 酪胺酸激酶抑制劑之眼用調配物的用途 |
| ES2894802T3 (es) | 2015-09-23 | 2022-02-15 | Aerpio Pharmaceuticals Inc | Activadores de Tie-2 para su uso en el tratamiento de la presión intraocular |
| EP3962482A4 (en) | 2019-04-29 | 2023-01-11 | EyePoint Pharmaceuticals, Inc. | TIE 2 ACTIVATORS FACING THE SCHLEMM CHANNEL |
| EP4028015A4 (en) * | 2019-09-13 | 2023-11-15 | Aldeyra Therapeutics, Inc. | Ophthalmic formulations of methotrexate |
| JP7653164B2 (ja) * | 2019-09-27 | 2025-03-28 | バージニア コモンウェルス ユニバーシティー | 組織を修復または増加させるための組成物および方法 |
| CN116251186B (zh) * | 2021-12-09 | 2025-04-25 | 成都瑞沐生物医药科技有限公司 | 一种酪氨酸激酶抑制剂眼用制剂及其制备方法和用途 |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3856919A (en) * | 1970-06-08 | 1974-12-24 | Burton Parsons Chemicals Inc | Ophthalmic solution |
| US4027020A (en) * | 1974-10-29 | 1977-05-31 | Millmaster Onyx Corporation | Randomly terminated capped polymers |
| US3931319A (en) * | 1974-10-29 | 1976-01-06 | Millmaster Onyx Corporation | Capped polymers |
| US4409205A (en) * | 1979-03-05 | 1983-10-11 | Cooper Laboratories, Inc. | Ophthalmic solution |
| US4525346A (en) * | 1981-09-28 | 1985-06-25 | Alcon Laboratories, Inc. | Aqueous antimicrobial ophthalmic solutions |
| US4407791A (en) * | 1981-09-28 | 1983-10-04 | Alcon Laboratories, Inc. | Ophthalmic solutions |
| US4727064A (en) * | 1984-04-25 | 1988-02-23 | The United States Of America As Represented By The Department Of Health And Human Services | Pharmaceutical preparations containing cyclodextrin derivatives |
| US4836986A (en) * | 1984-09-28 | 1989-06-06 | Bausch & Lomb Incorporated | Disinfecting and preserving systems and methods of use |
| US5002935A (en) * | 1987-12-30 | 1991-03-26 | University Of Florida | Improvements in redox systems for brain-targeted drug delivery |
| US5037647A (en) * | 1988-09-15 | 1991-08-06 | Alcon Laboratories, Inc. | Aqueous antimicrobial opthalmic solutions comprised of quaternary ammonium compound, citric acid, citrate and sodium chloride |
| US5461081A (en) * | 1989-09-28 | 1995-10-24 | Alcon Laboratories, Inc. | Topical ophthalmic pharmaceutical vehicles |
| US5932572A (en) * | 1992-02-21 | 1999-08-03 | Alcon Laboratories, Inc. | Topical anti-glaucoma compositions |
| US5300287A (en) * | 1992-11-04 | 1994-04-05 | Alcon Laboratories, Inc. | Polymeric antimicrobials and their use in pharmaceutical compositions |
| RU2108112C1 (ru) * | 1993-04-16 | 1998-04-10 | Вакамото Фармасьютикал Ко., Лтд. | Водная лекарственная композиция, обладающая свойством обратимого терморегулируемого гелеобразования |
| US6232343B1 (en) * | 1996-05-07 | 2001-05-15 | Toray Industries, Inc. | Ophthalmic preparations |
| DK1203808T3 (da) * | 1997-07-29 | 2005-01-31 | Alcon Lab Inc | Konditioneringsoplösninger til pleje af hårde kontaktlinser |
| JP4682495B2 (ja) * | 1999-09-06 | 2011-05-11 | 小野薬品工業株式会社 | 眼疾患の予防、治療剤 |
| JP2003510263A (ja) * | 1999-09-24 | 2003-03-18 | アルコン，インコーポレイテッド | シプロフロキサシンおよびデキサメタゾンを含有する局所用懸濁処方物 |
| WO2001039765A2 (en) * | 1999-12-03 | 2001-06-07 | Ista Pharmaceuticals, Inc. | Compositions and methods for the induction and treatment of retinal detachments |
| JP2003533464A (ja) * | 2000-05-15 | 2003-11-11 | フアルマシア・イタリア・エツセ・ピー・アー | 安定化ステロイド懸濁液 |
| JP2004504357A (ja) * | 2000-07-26 | 2004-02-12 | アルコン，インコーポレイテッド | ポリマー性懸濁化剤を含有しない薬学的懸濁組成物 |
| JP3450805B2 (ja) * | 2000-08-08 | 2003-09-29 | わかもと製薬株式会社 | 水性医薬組成物 |
| US20040256749A1 (en) * | 2000-12-22 | 2004-12-23 | Mahesh Chaubal | Process for production of essentially solvent-free small particles |
| US6743439B1 (en) * | 2001-06-27 | 2004-06-01 | Alcon, Inc. | Ophthalmic compositions containing copolymers of sulfonated styrene and maleic anhydride |
| CN1231218C (zh) * | 2001-09-21 | 2005-12-14 | 爱尔康公司 | 药物组合物在制备用于治疗中耳感染的药物中的用途 |
| US7001615B1 (en) * | 2001-12-07 | 2006-02-21 | Alcon, Inc. | Sustained release ophthalmic, otic and nasal suspension |
| IL165383A0 (en) * | 2002-06-21 | 2006-01-15 | Transform Pharmaceuticals Inc | Pharmaceutical compositions with improved dissolution |
| US20040235892A1 (en) * | 2003-05-22 | 2004-11-25 | Yujia Dai | Indazole and benzisoxazole kinase inhibitors |
| DK1638941T3 (da) * | 2003-05-22 | 2010-10-11 | Abbott Lab | Indazol-, benzisoxazol- og benzisothiazolkinaseinhibitorer |
| PL1755616T3 (pl) * | 2004-04-08 | 2014-10-31 | Eye Co Pty Ltd | Leczenie mineralokortykoidami retinopatii wysiękowej |
| TWI358290B (en) * | 2004-12-02 | 2012-02-21 | Alcon Inc | Topical nepafenac formulations |
| TW200640443A (en) * | 2005-02-23 | 2006-12-01 | Alcon Inc | Methods for treating ocular angiogenesis, retinal edema, retinal ischemia, and diabetic retinopathy using selective RTK inhibitors |
| BRPI0609227A2 (pt) * | 2005-05-10 | 2010-03-09 | Alcon Inc | composições de suspensão de nepafenac e outros fármacos oftálmicos, bem como uso das referidas composições no tratamento tópico de distúrbios oftálmicos |
| DK1906916T3 (da) * | 2005-05-10 | 2009-01-19 | Alcon Inc | Oftalmisk suspension, der omfatter et oftalmisk lægemiddel, en poloxamin og et tonicitetsregulerende glycolbaseret middel, anvendelse af sammensætningen til fremstilling af et medikament til behandling af oftalmiske lidelser |
| US20070149480A1 (en) * | 2005-12-23 | 2007-06-28 | Alcon, Inc. | PHARMACEUTICAL COMPOSITION FOR DELIVERY OF RECEPTOR TYROSINE KINASE INHIBITING (RTKi) COMPOUNDS TO THE EYE |
| EP1962803A1 (en) * | 2005-12-23 | 2008-09-03 | Alcon, Inc. | PHARMACEUTICAL FORMULATION FOR DELIVERY OF RECEPTOR TYROSINE KINASE INHIBITING (RTKi) COMPOUNDS TO THE EYE |
| US20070173538A1 (en) * | 2005-12-23 | 2007-07-26 | Alcon, Inc. | PHARMACEUTICAL FORMULATION FOR DELIVERY OF RECEPTOR TYROSINE KINASE INHIBITING (RTKi) COMPOUNDS TO THE EYE |
| US20070249546A1 (en) * | 2006-04-22 | 2007-10-25 | Sawaya Assad S | Ophthalmic and related aqueous solutions containing antifungal agents, uses therefor and methods for preparing them |
| KR20100051811A (ko) * | 2007-07-20 | 2010-05-18 | 알콘, 인코퍼레이티드 | 눈에 수용체 티로신 키나제 저해(ｒｔｋｉ) 화합물을 전달하기 위한 약제학적 제제 |
| TW201023912A (en) * | 2008-12-05 | 2010-07-01 | Alcon Res Ltd | Pharmaceutical suspension |
-
2010
- 2010-03-03 AU AU2010221438A patent/AU2010221438C1/en not_active Ceased
- 2010-03-03 JP JP2011553061A patent/JP5583145B2/ja not_active Expired - Fee Related
- 2010-03-03 CA CA2753837A patent/CA2753837A1/en not_active Abandoned
- 2010-03-03 CN CN201510767618.5A patent/CN105362221A/zh active Pending
- 2010-03-03 KR KR1020117023002A patent/KR20110123789A/ko not_active Ceased
- 2010-03-03 MX MX2011008680A patent/MX2011008680A/es active IP Right Grant
- 2010-03-03 WO PCT/US2010/025998 patent/WO2010101971A1/en not_active Ceased
- 2010-03-03 BR BRPI1008920-9A patent/BRPI1008920A2/pt not_active IP Right Cessation
- 2010-03-03 US US12/716,385 patent/US20100226992A1/en not_active Abandoned
- 2010-03-03 EP EP10749243.1A patent/EP2403342A4/en not_active Withdrawn
- 2010-03-03 CN CN2010800101411A patent/CN102340993A/zh active Pending
-
2011
- 2011-07-26 ZA ZA2011/05506A patent/ZA201105506B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012519692A5 (https=) | ||
| JP2012519694A5 (https=) | ||
| US11951103B2 (en) | Pharmaceutical composition | |
| HS Boddu et al. | Drug delivery to the back of the eye following topical administration: an update on research and patenting activity | |
| JP5583145B2 (ja) | レセプターチロシンキナーゼ阻害（ＲＴＫｉ）化合物の眼への送達のための薬学的組成物 | |
| JP2009521493A (ja) | 眼への受容体チロシンキナーゼ阻害（ＲＴＫｉ）化合物の送達のための医薬製剤 | |
| JP7716996B2 (ja) | 薬剤を含む水性組成物のｐＨを安定化させるための方法 | |
| TW202216119A (zh) | 眼用活性醫藥成分輸送的固態環糊精複合物製備 | |
| JP5934229B2 (ja) | 眼血管疾患の処置のための投与計画 | |
| RU2017112930A (ru) | Офтальмологические составы для доставки лекарств и защиты переднего отдела глаза | |
| JP2019524724A (ja) | テコビリマットの経口用医薬組成物及びその調製法 | |
| US20180009758A1 (en) | Multi-Tyrosine Kinase Inhibitors Derivatives and Methods of Use | |
| US20170342033A1 (en) | Multi-Tyrosine Kinase Inhibitors Derivatives and Methods of Use | |
| US20160376239A1 (en) | N-Acylalkyl Prodrugs of Multi-Tyrosine Kinase Inhibitors and Methods of Use | |
| Khan et al. | Ocular drug delivery: introduction and fundamental concept | |
| JP2019163227A (ja) | 医薬組成物 | |
| US10464902B1 (en) | Multi-tyrosine kinase inhibitors derivatives and methods of use | |
| US11623917B2 (en) | Multi-tyrosine kinase inhibitors derivatives and methods of use | |
| US20170020856A1 (en) | N-Acylalkyl Prodrugs of Multi-Tyrosine Kinase Inhibitors and Methods of Use | |
| US20170143688A1 (en) | Multi-Tyrosine Kinase Inhibitors Derivatives and Methods of Use | |
| CA3036474C (en) | Therapeutic agent for an ophthalmic disease comprising a vegf receptor inhibitor | |
| HK40007038A (en) | Medicinal composition comprising tivozanib | |
| US20170112821A1 (en) | Multi-Tyrosine Kinase Inhibitors Derivatives and Methods of Use | |
| HK40007038B (en) | Medicinal composition comprising tivozanib |